已核实 DOI 相关产品: 0

Low-molecular-weight soybean peptides alleviate hyperuricemia in mice through xanthine oxidase inhibition, gut microbiota modulation, and metabolic reprogramming

Journal 2026 · IF 6.2 · 发表于 2026 年 7 月 16 日
作者: Chen Wang,Jin Qian,Jiajing Liao,Lijuan Rao,Sen Mei,Bing Yuan,Tingting Geng,Haowei Fan,Guiming Fu,Yin Wan
阅读全文 在 PubMed 查看

摘要

Bioactive peptides are emerging as dietary modulators of hyperuricemia (HUA), yet the role of molecular weight in determining the efficacy of soybean peptides (SPs) remains unclear. This study evaluated the effects of different molecular weight SPs on HUA mice. Low-molecular-weight soybean peptides (LMW-SPs, <1 kDa and 1-3 kDa) exhibited superior uric acid-lowering effects, associated with stronger xanthine oxidase (XOD) inhibition. Six potential novel XOD-inhibiting peptides (FE, FPK, WK, PFK, GRYDDFF, and GRFESFF) were identified through virtual screening. Molecular docking analysis predicted that LMW-derived peptides interacted with the XOD active site through hydrogen bonds, π–π stacking, and hydrophobic interactions, suggesting their potential inhibitory effects on XOD activity. In vivo , LMW-SPs alleviated hepatic oxidative stress and renal injury while modulating gut microbiota and increasing short-chain fatty acid production. Serum metabolomics revealed that LMW-SPs altered tryptophan metabolism, characterized by decreased kynurenine pathway intermediates (e.g., L-formylkynurenine) and increased indole-related metabolites and serotonin, suggesting a metabolic shift toward microbiota-associated pathways. Overall, LMW-SPs alleviated HUA, and this effect was associated with reduced UA production and alterations in microbiota-associated metabolic profiles. These findings support the development of LMW-SPs as functional food ingredients for the nutritional management of HUA.